{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:59:05Z","timestamp":1790265545684,"version":"4.1.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2000,8]]},"DOI":"10.1023\/a:1006469621561","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T21:03:28Z","timestamp":1040504608000},"page":"231-241","source":"Crossref","is-referenced-by-count":41,"title":["The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery"],"prefix":"10.1007","volume":"18","author":[{"given":"Heleen A.","family":"Bardelmeijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"van Tellingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"267280_CR1","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.1998.16.7.2557","volume":"16","author":"MD Demario","year":"1998","unstructured":"Demario MD, Ratain MJ: Oral chemotherapy: Rationale and future directions. J Clin Oncol 16: 2557\u20132567, 1998","journal-title":"J Clin Oncol"},{"key":"267280_CR2","first-page":"479","volume":"9","author":"PM Hoff","year":"1998","unstructured":"Hoff PM, Pazdur R, Benner SE, Canetta R: UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 9: 479\u2013490, 1998","journal-title":"Anticancer Drugs"},{"key":"267280_CR3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548\u2013557, 1996","journal-title":"Anticancer Drugs"},{"key":"267280_CR4","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1998.16.5.1795","volume":"16","author":"DR Budman","year":"1998","unstructured":"Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16: 1795\u20131802, 1998","journal-title":"J Clin Oncol"},{"key":"267280_CR5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00685793","volume":"36","author":"MJ McKeage","year":"1995","unstructured":"McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer B, Santabarbara P, Harrap KR, Judson IR: A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36: 451\u2013458, 1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"267280_CR6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110\u2013115, 1997","journal-title":"J Clin Oncol"},{"key":"267280_CR7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00000421-199810000-00018","volume":"21","author":"S Kakolyris","year":"1998","unstructured":"Kakolyris S, Samonis G, Koukourakis M, Vlachonicolis I, Chalkiadakis G, Kalbakis K, Souglakos I, Agelaki S, Toloudis P, Georgoulias V: Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol 21: 505\u2013508, 1998","journal-title":"Am J Clin Oncol"},{"key":"267280_CR8","first-page":"4755","volume":"17","author":"C Gridelli","year":"1997","unstructured":"Gridelli C, Rossi A, Scognamiglio F, Guida C, Fiore F, Gatani T, Scoppa G, Pergola M: Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study. Anticancer Res 17: 4755\u20134758, 1997","journal-title":"Anticancer Res"},{"key":"267280_CR9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0149-2918(96)80036-1","volume":"18","author":"SD Sullivan","year":"1996","unstructured":"Sullivan SD, Mozaffari E, Johnson ES, Wolitz R, Follansbee SE: An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clin Ther 18: 546\u2013558, 1996","journal-title":"Clin Ther"},{"key":"267280_CR10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0009-9236(96)90208-8","volume":"60","author":"ET Hellriegel","year":"1996","unstructured":"Hellriegel ET, Bjornsson TD, Hauck WW: Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 60: 601\u2013607, 1996","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl2","key":"267280_CR11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000473853","volume":"29","author":"J Urquhart","year":"1996","unstructured":"Urquhart J: Patient compliance with crucial drug regimens: implications for prostate cancer. Eur Urol 29: Suppl 2: 124\u2013131, 1996","journal-title":"Eur Urol"},{"key":"267280_CR12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0305-7372(95)90022-5","volume":"21","author":"HA Davies","year":"1995","unstructured":"Davies HA, Lilleyman JS: Compliance with oral chemotherapy in childhood lymphoblastic leukaemia. Cancer Treat Rev 21: 93\u2013103, 1995","journal-title":"Cancer Treat Rev"},{"key":"267280_CR13","doi-asserted-by":"crossref","unstructured":"Macheras P, Reppas C, Dressman JB: Biopharmaceutics of orally administered drugs. 1st edition, Ellis Horwood, 1995","DOI":"10.3109\/9780203022849"},{"key":"267280_CR14","volume-title":"Clinical parmacokinetics: Concepts and applications","author":"M Rowland","year":"1995","unstructured":"Rowland M, Tozer TN: Clinical parmacokinetics: Concepts and applications. 3rd edition. Baltimore, Williams and Wilkins, 1995","edition":"3rd edition"},{"key":"267280_CR15","first-page":"39","volume":"6","author":"TT Kararli","year":"1989","unstructured":"Kararli TT: Gastro intestinal absorption of drugs. Crit Rev Ther Drug Carrier Syst 6: 39\u201386, 1989","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"267280_CR16","doi-asserted-by":"crossref","unstructured":"Rang HP, Dale MM: Pharmacology. 3rd edition. Churchill Livingstone, 1995","DOI":"10.1016\/B978-0-443-06911-6.50006-2"},{"key":"267280_CR17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/clpt.1991.137","volume":"50","author":"NR Hartman","year":"1991","unstructured":"Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Wyvill KM, Flora KP, Broder S, Johns DG: Pharmacokinetics of 20,30-dideoxyninosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther 50: 278\u2013285, 1991","journal-title":"Clin Pharmacol Ther"},{"key":"267280_CR18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF03189714","volume":"21","author":"L Williams","year":"1996","unstructured":"Williams L, Hill DP, Jr., Davis JA, Lowenthal DT: The influence of food on the absorption and metabolism of drugs: an update. Eur J Drug Metab Pharmacokinet 21: 201\u2013211, 1996","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"267280_CR19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1008629608556","volume":"19","author":"RM Hoetelmans","year":"1997","unstructured":"Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH: Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 19: 159\u2013175, 1997","journal-title":"Pharm World Sci"},{"key":"267280_CR20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1016086003070","volume":"13","author":"A Tsuji","year":"1996","unstructured":"Tsuji A, Tamai I: Carrier-mediated intestinal transport of drugs. Pharm Res 13: 963\u2013977, 1996","journal-title":"Pharm Res"},{"key":"267280_CR21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152\u2013162, 1976","journal-title":"Biochim Biophys Acta"},{"key":"267280_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.bi.58.070189.001033","volume":"58","author":"JA Endicott","year":"1989","unstructured":"Endicott JA, Ling V: The biochemistry of P-glycoproteinmediated multidrug resistance. Annu Rev Biochem 58: 137\u2013171, 1989","journal-title":"Annu Rev Biochem"},{"key":"267280_CR23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","volume":"62","author":"MM Gottesman","year":"1993","unstructured":"Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385\u2013427, 1993","journal-title":"Annu Rev Biochem"},{"key":"267280_CR24","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","volume":"84","author":"F Thiebaut","year":"1987","unstructured":"Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735\u20137738, 1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"267280_CR25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1006\/taap.1996.8086","volume":"143","author":"GR Lankas","year":"1997","unstructured":"Lankas GR, Cartwright ME, Umbenhauer D: P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 143: 357\u2013365, 1997","journal-title":"Toxicol Appl Pharmacol"},{"key":"267280_CR26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0890-6238(98)00027-6","volume":"12","author":"GR Lankas","year":"1998","unstructured":"Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR: Placental P-glycoprotein defiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12: 457\u2013463, 1998","journal-title":"Reprod Toxicol"},{"key":"267280_CR27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","volume":"77","author":"AH Schinkel","year":"1994","unstructured":"Schinkel AH, Smit JJM, Van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491\u2013502, 1994","journal-title":"Cell"},{"key":"267280_CR28","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.94.8.4028","volume":"94","author":"AH Schinkel","year":"1997","unstructured":"Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, van der Valk MA, Voordouw AC, Spits H, Van Tellingen O, Zijlmans JM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028\u20134033, 1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"267280_CR29","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","volume":"94","author":"A Sparreboom","year":"1997","unstructured":"Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031\u20132035, 1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"267280_CR30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2036.1987.tb00634.x","volume":"1","author":"DJ Back","year":"1987","unstructured":"Back DJ, Rogers SM: Review: first-pass metabolism by the gastrointestinal mucosa. Aliment Pharmacol Ther 1: 339\u2013357, 1987","journal-title":"Aliment Pharmacol Ther"},{"key":"267280_CR31","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","volume":"338","author":"JC Kolars","year":"1991","unstructured":"Kolars JC, Awni WM, Merion RM, Watkins PB: First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488\u20131490, 1991","journal-title":"Lancet"},{"key":"267280_CR32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2125.1992.tb04098.x","volume":"33","author":"IR Webber","year":"1992","unstructured":"Webber IR, Peters WHM, Back DJ: Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 33: 661\u2013664, 1992","journal-title":"Br J Clin Pharmacol"},{"key":"267280_CR33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0009-9236(95)90067-5","volume":"58","author":"DY Gomez","year":"1995","unstructured":"Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58: 15\u201319, 1995","journal-title":"Clin Pharmacol Ther"},{"key":"267280_CR34","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI116064","volume":"90","author":"JC Kolars","year":"1992","unstructured":"Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90: 1871\u20131878, 1992","journal-title":"J Clin Invest"},{"key":"267280_CR35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008571-199410000-00003","volume":"4","author":"JC Kolars","year":"1994","unstructured":"Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB: CYP3A gene expression in human gut epithelium. Pharmacogenetics 4: 247\u2013259, 1994","journal-title":"Pharmacogenetics"},{"key":"267280_CR36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2165\/00003088-199426020-00007","volume":"26","author":"DR Krishna","year":"1994","unstructured":"Krishna DR, Klotz U: Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26: 144\u2013160, 1994","journal-title":"Clin Pharmacokinet"},{"key":"267280_CR37","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","volume":"283","author":"MF Paine","year":"1997","unstructured":"Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE: Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. J Pharmacol Exp Ther 283: 1552\u20131562, 1997","journal-title":"J Pharmacol Exp Ther"},{"key":"267280_CR38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0090-9556(25)08440-5","volume":"22","author":"KS Lown","year":"1994","unstructured":"Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22: 947\u2013955, 1994","journal-title":"Drug Metab Dispos"},{"key":"267280_CR39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1096\/fasebj.6.2.1537465","volume":"6","author":"FP Guengerich","year":"1992","unstructured":"Guengerich FP: Characterization of human cytochrome P450 enzymes. FASEB J 6: 745\u2013748, 1992","journal-title":"FASEB J"},{"key":"267280_CR40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","volume":"13","author":"VJ Wacher","year":"1995","unstructured":"Wacher VJ, Wu CY, Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and 239 P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129\u2013134, 1995","journal-title":"Mol Carcinog"},{"key":"267280_CR41","first-page":"72","volume":"3","author":"FP Zeller","year":"1984","unstructured":"Zeller FP, Ueda CT, Wulf BG, Meyers DG: Effect of caffeine on the oral absorption and disposition of quinidine. Clin Pharm 3: 72\u201375, 1984","journal-title":"Clin Pharm"},{"key":"267280_CR42","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1016\/0006-2952(79)90592-6","volume":"28","author":"J Nakamura","year":"1979","unstructured":"Nakamura J, Takamura R, Kimura T, Muranishi S, Sezaki H: Enhancement effect of methylxanthines on the intestinal absorption of poorly absorbable dyes from the rat small intestine. Biochem Pharmacol 28: 2957\u20132960, 1979","journal-title":"Biochem Pharmacol"},{"key":"267280_CR43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.2042-7158.1979.tb13501.x","volume":"31","author":"DA Whitmore","year":"1979","unstructured":"Whitmore DA, Brookes LG, Wheeler KP: Relative effects of different surfactants on intestinal absorption and the release of proteins and phospholipids from the tissue. J Pharm Pharmacol 31: 277\u2013283, 1979","journal-title":"J Pharm Pharmacol"},{"key":"267280_CR44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0168-3659(95)00147-6","volume":"39","author":"LZ Benet","year":"1996","unstructured":"Benet LZ, Wu CY, Hebert MF, Wacher VJ: Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Contr Release 39: 139\u2013143, 1996","journal-title":"J Contr Release"},{"key":"267280_CR45","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.1995.13.8.2039","volume":"13","author":"SL Berg","year":"1995","unstructured":"Berg SL, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP, Cowan KH, Balis FM: Effect of Rverapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 13: 2039\u20132042, 1995","journal-title":"J Clin Oncol"},{"key":"267280_CR46","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1200\/JCO.1994.12.9.1771","volume":"12","author":"GC Wishart","year":"1994","unstructured":"Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 12: 1771\u20131777, 1994","journal-title":"J Clin Oncol"},{"key":"267280_CR47","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1200\/JCO.1992.10.11.1730","volume":"10","author":"E Solary","year":"1992","unstructured":"Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M, Guy H: Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukernia. J Clin Oncol 10: 1730\u20131736, 1992","journal-title":"J Clin Oncol"},{"key":"267280_CR48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ijc.2910480422","volume":"48","author":"WTA van der Graaf","year":"1991","unstructured":"van der Graaf WTA, de Vries EGE, Uges DRA, Nanninga AG, Meijer C, Vellenga E, Mulder POM, Mulder NH: In vitro and in vivo modulation of multidrug resistance with amiodarone. Int J Cancer 48: 616\u2013622, 1991","journal-title":"Int J Cancer"},{"key":"267280_CR49","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/0959-8049(96)00091-3","volume":"32A","author":"DR Ferry","year":"1996","unstructured":"Ferry DR, Traunecker H, Kerr DJ: Clinical trials of Pglycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070\u20131081, 1996","journal-title":"Eur J Cancer"},{"key":"267280_CR50","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/bjc.1997.127","volume":"75","author":"G Toffoli","year":"1997","unstructured":"Toffoli G, Sorio R, Gigante M, Corona G, Galligioni E, Boiocchi M: Cyclosporin A as a multi drug-resistant modulator in patients with renal cell carcinoma treated with teniposide. Br J Cancer 75: 715\u2013721, 1997","journal-title":"Br J Cancer"},{"key":"267280_CR51","first-page":"4226","volume":"51","author":"D Boesch","year":"1991","unstructured":"Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F: In vivo circumvention of P-glycoproteinmediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226\u20134233, 1991","journal-title":"Cancer Res"},{"key":"267280_CR52","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/03008916970831s110","volume":"83","author":"A Covelli","year":"1997","unstructured":"Covelli A: SDZ PSC 833: A new multidrug-resistance modulator. Tumori 83: S21-S24, 1997","journal-title":"Tumori"},{"key":"267280_CR53","first-page":"4595","volume":"53","author":"F Hyafil","year":"1993","unstructured":"Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595\u20134602, 1993","journal-title":"Cancer Res"},{"key":"267280_CR54","first-page":"3641","volume":"58","author":"CL Booth","year":"1998","unstructured":"Booth CL, Brouwer KR, Brouwer KLR; Effect of multidrug resistance modulators on the hepatobillary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res 58: 3641\u20133648, 1998","journal-title":"Cancer Res"},{"key":"267280_CR55","first-page":"4171","volume":"56","author":"AH Dantzig","year":"1996","unstructured":"Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ: Reversal of Pglycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171\u20134179, 1996","journal-title":"Cancer Res"},{"key":"267280_CR56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0065-2571(96)00021-0","volume":"37","author":"JJ Starling","year":"1997","unstructured":"Starling JJ, Shepard RL, Cao J, Law KL, Norman BH, Kroin JS, Ehlhardt WJ, Baughman TM, Winter MA, Bell MG, Shih C. Gruber J, Elmquist WF, Dantzig AH: Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 37: 335\u2013347, 1997","journal-title":"Adv Enzyme Regul"},{"key":"267280_CR57","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","volume":"268","author":"T Saeki","year":"1993","unstructured":"Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268: 6077\u20136080, 1993","journal-title":"J Biol Chem"},{"key":"267280_CR58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1432-1033.1994.tb18748.x","volume":"221","author":"EC Spoelstra","year":"1994","unstructured":"Spoelstra EC, Westerhoff HV, Pinedo HM, Dekker H, Lankelma J: The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur J Biochem 221: 363\u2013373, 1994","journal-title":"Eur J Biochem"},{"key":"267280_CR59","first-page":"603","volume":"7","author":"A Archinal-Mattheis","year":"1995","unstructured":"Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW, Cohen D: Analysis of the interactions of SDZ PSC 833 ([30-keto-Bmt1]Val2]-cyclosporine), a multidrug resistance modulator, with Pglycoprotein. Oncol Res 7: 603\u2013610, 1995","journal-title":"Oncol Res"},{"key":"267280_CR60","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/0277-5379(91)90435-G","volume":"27","author":"PR Twentyman","year":"1991","unstructured":"Twentyman PR, Bleehen NM: Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27: 1639\u20131642, 1991","journal-title":"Eur J Cancer"},{"key":"267280_CR61","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/jnci\/90.15.1161","volume":"90","author":"AJ Smith","year":"1998","unstructured":"Smith AJ, Mayer U, Schinkel AH, Borst P: Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Nat Cancer Inst 90: 1161\u20131166, 1998","journal-title":"J Nat Cancer Inst"},{"key":"267280_CR62","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<729::AID-IJC19>3.0.CO;2-Z","volume":"76","author":"L Jette","year":"1998","unstructured":"Jette L, Murphy GF, Beliveau R: Drug binding to Pglycoprotein is inhibited in normal tissues following SDZPSC 833 treatment. Int J Cancer 76: 729\u2013737, 1998","journal-title":"Int J Cancer"},{"key":"267280_CR63","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/bjc.1997.530","volume":"76","author":"J van Asperen","year":"1997","unstructured":"van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH: Enhanced oral bioavailability of paclitaxel in mice treated with the Pglycoprotein blocker SDZ PSC 833. Br J Cancer 76: 1181\u20131183, 1997","journal-title":"Br J Cancer"},{"key":"267280_CR64","first-page":"2293","volume":"4","author":"J van Asperen","year":"1998","unstructured":"van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH: Enhanced oral absorption and decreased elimination of paclitaxel in mice with cyclosporin A. Clin Cancer Res 4: 2293\u20132297, 1998","journal-title":"Clin Cancer Res"},{"key":"267280_CR65","first-page":"4026","volume":"54","author":"JW Harris","year":"1994","unstructured":"Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM: Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54: 4026\u20134035, 1994","journal-title":"Cancer Res"},{"key":"267280_CR66","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(98)24030-X","volume":"352","author":"JM Meerum Terwogt","year":"1998","unstructured":"Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Schellens JHM: Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352: 285, 1998","journal-title":"Lancet"},{"key":"267280_CR67","first-page":"463P","volume":"47","author":"MM Malingr\u00e9","year":"1999","unstructured":"Malingr\u00e9 MM, Schellens JHM, Duchin K, Rosing H, Beijnen JH: Oral paclitaxel in a twice daily dose regimen. Br J Clin Pharmacol 47: 463P, 1999","journal-title":"Br J Clin Pharmacol"},{"key":"267280_CR68","first-page":"166a","volume":"18","author":"MM Malingr\u00e9","year":"1999","unstructured":"Malingr\u00e9 MM, Meerum Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, ten Bokkel Huinink WW, Swart M, Duchin K, Schellens JHM: Clinical pharmacology of oral paclitaxel in a dose escalating study. Proc Am Soc Clin Oncol 18: 166a, 1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"267280_CR69","first-page":"190a","volume":"18","author":"JM Meerum Terwogt","year":"1999","unstructured":"Meerum Terwogt JM, Malingr\u00e9 MM, Beijnen JH, van Tellingen O, Rosing H, Koopman FJ, ten Bokkel Huinink WW, Swart M, Duchin K, Schellens JHM: Mass balance of paclitaxel (Paxene) in humans after both intravenous and oral administration. Proc Am Soc Clin Oncol 18: 190a, 1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"267280_CR70","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/0006-2952(94)90580-0","volume":"48","author":"P Wils","year":"1994","unstructured":"Wils P, Phung-Ba V, Warnery A, Lechardeur D, Racissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotcin in human intestinal epithelial cell monolayers. Biochem Pharmacol 48: 1528\u20131530, 1994","journal-title":"Biochem Pharmacol"},{"key":"267280_CR71","first-page":"201a","volume":"18","author":"DJ Richel","year":"1999","unstructured":"Richel DJ, Malingr\u00e9 MM, ten Bokkel Huinink WW, Rosing H. van Tellingen O, Swart M, Beijnen JH, Schellens JHM: Cyclosporin A strongly enhances the oral bioavallability of docetaxel in cancer patients. Proc Am Soc Clin Oncol 18: 201a, 1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"267280_CR72","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00254536","volume":"7","author":"M D'Incalci","year":"1982","unstructured":"D'Incalci M, Farina P, Sessa C, Mangioni C, Conter V, Masera G, Rocchetti M, Pisoni MB, Piazza E, Beer M, Cavalli F: Pharmacokinetics of VP 16\u2013213 given by different administration methods. Cancer Chemother Pharmacol 7: 141\u2013145, 1982","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl2","key":"267280_CR73","first-page":"48","volume":"12","author":"RD Smyth","year":"1985","unstructured":"Smyth RD, Pfeffer M, Scalzo A, Comis RL: Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 12, Suppl 2: 48\u201351, 1985","journal-title":"Semin Oncol"},{"key":"267280_CR74","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0277-5379(85)90310-4","volume":"21","author":"VJ Harvey","year":"1985","unstructured":"Harvey VJ, Slevin ML, Joel SP, Smythe MM, Johnston A, Wrigley PFM: Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 21: 1315\u20131319, 1985","journal-title":"Eur J Cancer Clin Oncol"},{"key":"267280_CR75","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/jnci\/84.5.348","volume":"84","author":"B Desoize","year":"1992","unstructured":"Desoize B, Woirin V, Legros M, Coninx P. Reduced oral etoposide bioavailability in patients with advanced cancer of the head and neck. J Natl Cancer Inst 84: 348\u2013350, 1992","journal-title":"J Natl Cancer Inst"},{"key":"267280_CR76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002800050718","volume":"41","author":"L Nguyen","year":"1998","unstructured":"Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochon I, Bachaud JM, Pujol A, Houin G, Bugat R, Canal P: Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 41: 125\u2013132, 1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"267280_CR77","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF00256172","volume":"16","author":"VJ Harvey","year":"1986","unstructured":"Harvey VJ, Slevin NIL, Joel SP, Johnston A, Wrigley PFM: The effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol 16: 178\u2013181, 1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"267280_CR78","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00304768","volume":"24","author":"ML Slevin","year":"1989","unstructured":"Slevin ML, Joel SP, Whomsley R, Devenport K, Harvey VJ, Osborne RJ, Wrigley PFM: The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24: 329\u2013331, 1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"267280_CR79","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.1993.11.2.374","volume":"11","author":"KR Hande","year":"1993","unstructured":"Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH: Bioavailability of low-dose oral etoposide. J Clin Oncol 11: 374\u2013377, 1993","journal-title":"J Clin Oncol"},{"issue":"SupplC","key":"267280_CR80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0305-7372(93)90046-T","volume":"19","author":"FA Greco","year":"1993","unstructured":"Greco FA: Chronic etoposide administration: overview of clinical experience. Cancer Treat Rev 19, Suppl C: 35\u201345, 1993","journal-title":"Cancer Treat Rev"},{"key":"267280_CR81","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.1992.10.10.1635","volume":"10","author":"BL Lum","year":"1992","unstructured":"Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635\u20131642, 1992","journal-title":"J Clin Oncol"},{"key":"267280_CR82","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.2910510316","volume":"51","author":"RP Keller","year":"1992","unstructured":"Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC: Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16\u2013213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51: 433\u2013438, 1992","journal-title":"Int J Cancer"},{"key":"267280_CR83","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s002800050258","volume":"35","author":"BL Leu","year":"1995","unstructured":"Leu BL, Huang JD: Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35: 432\u2013436, 1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"267280_CR84","first-page":"471","volume":"15","author":"K Kobayashi","year":"1996","unstructured":"Kobayashi K, Ratain MJ, Fleming GF, Vogelzang NJ, Cooper N, Sun BL: A phase I study of CYP3A4 modulation of oral etoposide with ketoconazoleconazol in patients with advanced cancer. Proc Am Soc Clin Oncol 15: 471, 1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"267280_CR85","first-page":"190a","volume":"17","author":"DR Shepard","year":"1998","unstructured":"Shepard DR, Kobayashi K, Wang C, Ratain MJ: Population pharmacokinetic determination of the modulation of oral etoposide (VP-16) elimination by ketoconazole. Proc Am Soc Clin Oncol 17: 190a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"267280_CR86","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0022-5347(17)34999-6","volume":"151","author":"MJ Siegsmund","year":"1994","unstructured":"Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM: Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151: 485\u2013491, 1994","journal-title":"J Urol"},{"key":"267280_CR87","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF00685117","volume":"27","author":"DJ Stewart","year":"1991","unstructured":"Stewart DJ, Grewaal D, Green RM, Verma S, Maroun JA, Redmond D, Robillard L, Gupta S: Bioavailability and pharmacology of oral idarubecin. Cancer Chermother Pharmacol 27: 308\u2013314, 1991","journal-title":"Cancer Chermother Pharmacol"},{"key":"267280_CR88","first-page":"707","volume":"10","author":"E Schleyer","year":"1996","unstructured":"Schleyer E, Kuhn S, Ruhrs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Straubel G, Hiddemann W: Oral idarubicin pharmacokinetics-correlation of trough level with idarubicin area under curve. Leukemia 10: 707\u2013712, 1996","journal-title":"Leukemia"},{"key":"267280_CR89","first-page":"1792","volume":"9","author":"D Damiani","year":"1995","unstructured":"Damiani D, Michieli M, Michelutti A, Pea F, Baraldo M, Fanin R, Russo D, Furlanut M, Baccarani M: P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases. Leukemia 9: 1792\u20131795, 1995","journal-title":"Leukemia"},{"key":"267280_CR90","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s002800050552","volume":"39","author":"M Tolomeo","year":"1996","unstructured":"Tolomeo M, Gancitano RA, Musso M, Porretto F, Perricone R, Abbadessa V, Cajozzo A: Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells. Cancer Chemother Pharmacol 39: 157\u2013161, 1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"267280_CR91","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s002800050514","volume":"38","author":"U Tidefelt","year":"1996","unstructured":"Tidefelt U, Prenkert M, Paul C: Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrugresistant HL60 cells. Cancer Chemother Pharmacol 38: 476\u2013480, 1996","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl3","key":"267280_CR92","first-page":"S32","volume":"10","author":"S Hegewisch-Becker","year":"1996","unstructured":"Hegewisch-Becker S: MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia 10, Suppl 3: S32-S38, 1996","journal-title":"Leukemia"},{"key":"267280_CR93","first-page":"41","volume":"2","author":"JP Armand","year":"1989","unstructured":"Armand JP, Marty M: Navelbine: a new step in cancer therapy? Semin Oncol 2: 41\u201345, 1989","journal-title":"Semin Oncol"},{"key":"267280_CR94","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF00686338","volume":"29","author":"XJ Zhou","year":"1991","unstructured":"Zhou XJ, Bore P, Monjanel S, Sahnoun Z, Favre R, Durand A, Rahinani R: Pharmacokinctics of navelbine after oral administration in cancer patients. Cancer Chemother Pharmacol 29: 66\u201370, 1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"267280_CR95","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1073\/pnas.84.9.3004","volume":"84","author":"K Ueda","year":"1987","unstructured":"Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of full-length DNA for the human MDR1 gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84: 3004\u20133008, 1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"267280_CR96","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3727\/095535491820873335","volume":"3","author":"MB Meyers","year":"1991","unstructured":"Meyers MB, Scotto KW, Sirotnak FM: P-glycoprotein content and mediation of vincristine efflux: correlation with the level of differentiation in luminal epithelium of mouse small intestine. Cancer Commun 3: 159\u2013165, 1991","journal-title":"Cancer Commun"},{"key":"267280_CR97","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/bdd.2510150705","volume":"15","author":"XJ Zhou","year":"1994","unstructured":"Zhou XJ, Zhou-Pan XR, Favre R, Rahmani R: Relative bioavailability of two oral formulations of navelbine in cancer patients. Biopharm Drug Dispos 15: 577\u2013586, 1994","journal-title":"Biopharm Drug Dispos"},{"key":"267280_CR98","unstructured":"Lucas S, Donehower RC, Rowinsky EK, Trump DL, Weiner E,WarginWA, Hohneker JA: Absolute bioavailability (ABA) and pharmacokinetics of weekly navelbine (NVB) liquid filled soft gelatin capsules at full therapeutic doses in patients (pts) with solid tumors. Proc 7th NIC-EORTC Symposium on New Drugs in Cancer Therapy abstract 264, March 17\u201320, 1992"},{"key":"267280_CR99","first-page":"1699","volume":"12","author":"O van Tellingen","year":"1992","unstructured":"van Tellingen O, Sips JHM, Beijnen JH, Bult A, Nooijen WJ: Pharmacology, bioanalysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives. Anticancer Res 12: 1699\u20131716, 1992","journal-title":"Anticancer Res"},{"key":"267280_CR100","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bjc.1996.243","volume":"731","author":"JHM Schellens","year":"1996","unstructured":"Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, Verweij J: Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 731: 1268\u20131271, 1996","journal-title":"Br J Cancer"},{"key":"267280_CR101","unstructured":"Herben VMM, Schellens JH, ten Bokkel Huinink WW, Rosing H, van Zomeren DM, Batchelor FB, Beusenberg FB, Beijnen JH: The effect of food co-administration on the pharmacokinetics of topotecan gelatin capsules. Proc Am Soc Clin Oncol 17: 1999"},{"key":"267280_CR102","first-page":"2268","volume":"52","author":"CB Hendricks","year":"1992","unstructured":"Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268\u20132278, 1992","journal-title":"Cancer Res"},{"key":"267280_CR103","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s002800050682","volume":"40","author":"Y Hoki","year":"1997","unstructured":"Hoki Y, Fujimori A, Pommier Y: Differential cytotoxicity of clinically important camptothecin derivatives in Pglycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 40: 433\u2013438, 1997","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"267280_CR104","first-page":"S44","volume":"42","author":"Y Sugiyarna","year":"1998","unstructured":"Sugiyarna Y, Kato Y, Chu XY: Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 42, Suppl: S44\u20139, 1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"267280_CR105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/bjc.1998.58","volume":"77","author":"WJM Jansen","year":"1998","unstructured":"Jansen WJM, Hulscher TM, van Ark-Otte J, Giaccone G, Pinedo HM, Boven E: CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistanceassociated protein. Br J Cancer 77: 359\u2013365, 1998","journal-title":"Br J Cancer"},{"key":"267280_CR106","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215\u2013237, 1989","journal-title":"Clin Pharmacokinet"},{"key":"267280_CR107","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2125.1979.tb04651.x","volume":"7","author":"RE Finch","year":"1979","unstructured":"Finch RE, Bending MR, Lant AF: Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol 7: 613\u2013617, 1979","journal-title":"Br J Clin Pharmacol"},{"key":"267280_CR108","first-page":"723","volume":"58","author":"JL Cohen","year":"1974","unstructured":"Cohen JL, Irwin LE, Marshall GJ, Darvey H, Bateman JR: Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cancer Chemother Rep 58: 723\u2013731, 1974","journal-title":"Cancer Chemother Rep"},{"key":"267280_CR109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2165\/00003088-197803040-00006","volume":"3","author":"N Chirstophidis","year":"1978","unstructured":"Chirstophidis N, Vajda FJ, Lucas I, Drummer O, Moon WJ, Louis WJ: Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 3: 330\u2013336, 1978","journal-title":"Clin Pharmacokinet"},{"key":"267280_CR110","first-page":"5405","volume":"45","author":"FN Naguib","year":"1985","unstructured":"Naguib FN, el Kouni MH, Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405\u20135412, 1985","journal-title":"Cancer Res"},{"key":"267280_CR111","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE, Song R, Soong SJ, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197\u2013201, 1990","journal-title":"Cancer Res"},{"key":"267280_CR112","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/0006-2952(93)90615-4","volume":"46","author":"T Spector","year":"1993","unstructured":"Spector T, Harrington JA, Porter DJ: 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243\u20132248, 1993","journal-title":"Biochem Pharmacol"},{"key":"267280_CR113","doi-asserted-by":"crossref","first-page":"11064","DOI":"10.1073\/pnas.90.23.11064","volume":"90","author":"DP Baccanari","year":"1993","unstructured":"Baccanari DP, Davis ST, Knick VC, Spector T: 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 90: 11064\u201311068, 1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"267280_CR114","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.1996.14.12.3085","volume":"14","author":"SD Baker","year":"1996","unstructured":"Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14: 3085\u20133096, 1996","journal-title":"J Clin Oncol"},{"issue":"Suppl7","key":"267280_CR115","first-page":"48","volume":"12","author":"R Pazdur","year":"1998","unstructured":"Pazdur R, Hoff PM, Medgyesy D, Royce M, Brito R: The oral fluorouracil prodrugs. Oncology (Huntingt) 12, Suppl 7: 48\u201351, 1998","journal-title":"The oral fluorouracil prodrugs. Oncology (Huntingt)"},{"key":"267280_CR116","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00255750","volume":"10","author":"MI Anttila","year":"1983","unstructured":"Anttila MI, Sotaniemi EA, Kairaluoma MI, Mokka RE, Sundquist HT: Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10: 150\u2013153, 1983","journal-title":"Cancer Chemother Pharmacol"},{"key":"267280_CR117","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/00001813-199810000-00012","volume":"9","author":"M Fukushima","year":"1998","unstructured":"Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, Shirasaka T: Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 9: 817\u2013823, 1998","journal-title":"Anticancer Drugs"},{"key":"267280_CR118","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1248\/cpb.31.175","volume":"31","author":"A Kono","year":"1983","unstructured":"Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H: Activation of 50deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo) 31: 175\u2013178, 1983","journal-title":"Chem Pharm Bull (Tokyo)"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006469621561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006469621561\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006469621561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:56:26Z","timestamp":1753818986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006469621561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["267280"],"URL":"https:\/\/doi.org\/10.1023\/a:1006469621561","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]}}}